1431329-06-4 Usage
Description
(2R,3S,4S)-2,3,4-tris(benzyloxy)-4-(4-((benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methylpiperazin-1-yl)butan-1-one is a complex organic compound with a unique molecular structure. It is characterized by its chiral centers at the 2nd, 3rd, and 4th carbon atoms, which are in the R, S, and S configurations, respectively. The molecule contains multiple benzyloxy groups and a 1,3-dioxolan ring, as well as a 4-methylpiperazin-1-yl group attached to the 1st carbon. (2R,3S,4S)-2,3,4-tris(benzyloxy)-4-(4-((benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methylpiperazin-1-yl)butan-1-one is an intermediate in the synthesis of Ertugliflozin, a drug used for the treatment of type 2 diabetes.
Uses
Used in Pharmaceutical Industry:
(2R,3S,4S)-2,3,4-tris(benzyloxy)-4-(4-((benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-1-(4-methylpiperazin-1-yl)butan-1-one is used as an intermediate in the synthesis of Ertugliflozin (1210344-57-2), an antidiabetic agent. It plays a crucial role in the development of medications for the treatment of type 2 diabetes, helping to manage blood sugar levels and improve the quality of life for patients with this condition.
Additionally, this compound may have potential applications in other areas of the pharmaceutical industry, such as the development of new drugs or the enhancement of drug delivery systems. However, further research and development would be required to explore these possibilities.
Check Digit Verification of cas no
The CAS Registry Mumber 1431329-06-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,3,1,3,2 and 9 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1431329-06:
(9*1)+(8*4)+(7*3)+(6*1)+(5*3)+(4*2)+(3*9)+(2*0)+(1*6)=124
124 % 10 = 4
So 1431329-06-4 is a valid CAS Registry Number.
1431329-06-4Relevant articles and documents
METHODS FOR PREPARING SGLT2 INHIBITORS
-
Page/Page column 33-35; 13, (2014/10/15)
This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.